News

Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product

Infant Bacterial Therapeutics AB (IBT) whose mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies and BioConnection, a leading pharmaceutical Contract Manufacturing Organisation (CMO), announced the initiation of Process Performance Qualification (PPQ) for the Drug Product (DP) for IBT’s lead Live Biotherapeutic Product, IBP-9414. The DP PPQ programme will be conducted at BioConnection’s manufacturing facility in Oss, the Netherlands. Alexander Willemse, CEO at BioConnection, said: “ After conducting successful manufacturing tests in close collaboration with the IBT team, we are proud to announce that we are taking the next step together to bring their life-saving product to market. Their…

read more…

Let’s connect

If you’re exploring fill & finish support for an upcoming or ongoing program, we’d love to learn more about your goals and how we can contribute to your success. Whether you’re evaluating partners for a new project or preparing for your next development milestone, our team is ready to support you with clarity, expertise, and flexibility.

Share a few details about your molecule, timelines, or specific challenges, and we’ll follow up with insights tailored to your needs. By understanding your priorities early, we can determine how our capabilities, capacity, and approach align with your plans. We’re here to help.